Phillips Medisize Brand Guidelines: A 1964 Wisconsin Moulder, a Finnish Merger & Molex

A Wisconsin moulder that bought a Finnish one.

Phillips Medisize began as Phillips Plastics. In July 2014 the University of Wisconsin–Madison reported that Robert Cervenka, who had studied under the university’s plastics professor Ronald Daggett, founded the company in 1964, and described it as possibly the largest plastics firm in Wisconsin. The same report already used the newer name, Phillips-Medisize.

By 2011 Phillips was a large contract manufacturer. Cleanroom Technology reported on 12 July 2011 that it made high-tech products and injection-moulded plastic and metal parts, employed 1,400 people in 14 locations across the US, Europe and China, ran design centres in Wisconsin and California, and had four facilities able to work in Class 8 cleanrooms.

The second half of the name came from Finland. In the same report, Cleanroom Technology said Phillips had agreed to buy Medisize from the Swedish private equity group Ratos. Medisize was based in Vantaa, Finland, employed 850 people and made medical devices for drug delivery and pharmaceutical packaging, along with single-use plastic products for anaesthesia and intensive care, at sites in Finland, the Irish Republic, the Netherlands, Sweden and the Czech Republic. The sale was expected to complete the following month. Phillips said at the time that the deal would make it “one of the medical industry’s largest and most complete global providers of outsourced medical design and manufacturing services.”

The merged business traded as Phillips-Medisize, with a hyphen, in the years that followed. Its own website now writes the name without one, as Phillips Medisize, and this guide follows that spelling.

Pens, autoinjectors and inhalers for pharma customers.

Pharmaceutical Technology describes Phillips Medisize as a company that designs and makes products for the pharmaceutical drug-delivery, in-vitro diagnostic and medtech markets. The company calls itself a contract development and manufacturing organisation, or CDMO, and its stated vision is “to be the preferred CDMO partner of choice for leading global customers.”

Its website groups its own device platforms under pharmaceutical work. The Envoi Pen Injector is, the company says, a compact pen for self-administered injectable medicines, including insulin and GLP-1 drugs, designed for 3.0 ml and 1.5 ml cartridges and currently offered for 3 ml cartridges. The Aria Smart Autoinjector is described as a device the company is developing: a reusable, rechargeable drive unit with optional Bluetooth Low Energy connectivity, paired with a single-use cassette that holds a 1 ml or 2.25 ml prefilled syringe. The site also lists dry powder inhalers, metered dose inhalers and the FOX vibrating mesh nebuliser.

Beyond its own platforms, the website lists injection moulding, two-shot and liquid silicone rubber moulding, automated assembly, labelling, packaging, sterilisation management and computed-tomography metrology, along with testing of injector pens to ISO 11608 and of prefilled syringes to ISO 11040. It also lists medical connectors, fibre optics and capillary tubing, and non-medical work for automotive, consumer and defence customers. The company says its people work in 30 locations around the world; its locations list includes Cambridge and Chippenham in England.

The pharmaceutical side grew again in 2025. Pharmaceutical Technology reported on 7 January 2025 that Molex, Phillips Medisize’s parent, had completed the purchase of Vectura Group of Chippenham from Vectura Fertin Pharma, a subsidiary of Philip Morris International. The deal, first announced in September 2024, added Vectura’s dry powder inhalers, metered dose inhalers, nasal inhalers and nebulisers, along with formulation and development services, and about 350 employees to a workforce of more than 6,000 at 30 sites in North America, Europe and Asia. English Wikipedia describes Vectura as a British company that develops inhaled medicines and makes inhaler devices, and says it was listed on the London Stock Exchange until Philip Morris International acquired it in 2021.

How drug-delivery makers present themselves.

Drug-delivery device makers sell mostly to other companies. Their customers are pharmaceutical and biotech firms that fill a pen, an autoinjector or a prefilled syringe with their own medicine and put their own name on the box, so the device maker’s brand often lives one step back from the patient. That shapes how these companies present themselves: less as consumer brands, more as engineering partners that can be trusted with a drug company’s product.

The pictures follow from that. The typical image is a clean render of a pen or autoinjector on a white or pale ground, often shown from several angles or in a technical cutaway that reveals the spring, the plunger and the syringe inside. Product families are usually named as platforms, with one prefix running across a range, and shown in neutral greys and whites so that a customer can imagine its own colours on the device.

Production is the other recurring theme. Websites and brochures show cleanroom assembly lines, injection-moulding machines, operators in gowns and hairnets, and gloved hands holding glass syringes, cartridges and vials. These images carry the message that the work is precise and controlled, and they sit beside pages on quality systems, regulatory support and human-factors testing with patients.

Much of the industry’s public face is seen at trade shows. Makers book stands at events such as CPHI, the pharmaceutical ingredients and packaging fair, Pharmapack in Paris, and the conferences of the Parenteral Drug Association, where they show new platforms to drug companies. The visual language there is the same: white stands, large product renders, cutaway models and short films of devices being assembled and used.

A Molex company, owned by Koch.

Phillips Medisize has belonged to Molex since 2016. English Wikipedia, citing Medical Plastics News of 7 November 2016, says Molex acquired the Wisconsin-based company in November 2016, when it employed about 5,400 people in 21 locations, and that it operates as an indirect subsidiary of Molex. Pharmaceutical Technology gives Molex’s headquarters as Lisle, Illinois, and confirms the 2016 purchase.

Molex in turn belongs to Koch of Wichita, Kansas. The Phillips Medisize website sets out that chain on its own pages: “Phillips Medisize is a Molex company, and Molex … is owned by Koch.” Its footer signs off as “Phillips Medisize – a Molex company,” and the site argues that private ownership lets it plan around long customer contracts rather than quarterly results. Those are the company’s own descriptions of its structure and approach.

The Vectura purchase shows how the group now works: the 2025 announcement named Molex as the buyer, while Pharmaceutical Technology described the deal as Phillips Medisize’s acquisition, and Vectura’s chief scientific officer took the same role, together with a vice-president post, in the Phillips Medisize medical business.

For a design guide, Phillips Medisize shows how a contract maker builds a name from a merger, keeps both founders’ names in it, and then sits as one brand inside a larger industrial group. Compare West Pharmaceutical Services, another American supplier to drug makers, and BD. For this guide we use a deep navy, a teal and a clean white with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Phillips Medisize’s identity on hand — save it to a board in the Made Good inspiration library.